Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Celsis launches ReACT microbial detection assay
According to Celsis, ReACT assays use proprietary selections of ribosomal RNA sequences to confirm or to rule out the presence of Gram-negative organisms, Staphylococcus aureus, yeast and mold,
According to Celsis, ReACT assays use proprietary selections of ribosomal RNA sequences to confirm or to rule out the presence of Gram-negative organisms, Staphylococcus aureus, yeast and mold,
A total of 26 subjects completed either 12 or 24 weeks of treatment during Phase II studies – 23 of the 26 subjects continue to receive treatment in
The first phase of this collaboration grant will be a feasibility study using reagents developed by Foundation for Innovative New Diagnostics (FIND) to develop assays on the Ramp
The transaction will be effected by an exchange of Akela common shares for the outstanding shares of Nventa on the basis of 0.0355 Akela shares for each Nventa
Specifically, the organizations hope to expand user access to the advanced quantitative analysis packages currently offered through GE Healthcare by offering workflow and diagnostic reporting efficiencies. GE Healthcare
The topiramate tablets are therapeutically equivalent to Topamax tablets from Ortho-McNeil Janssen Pharmaceuticals and are available in four strengths: 25mg, 50mg, 100mg and 200mg. Topiramate, an anticonvulsant, is
Sagent will offer azithromycin in a 500mg vial for intravenous use. The company anticipates the launch of azithromycin in April 2009. Under a joint venture agreement, Sagent and
Conserv-1 is a Phase II trial evaluating the safety, efficacy and clinical outcomes of various doses of ecallantide for the reduction of blood loss volume during on-pump cardiothoracic
With more than 30 years of experience in the pharmaceutical industry, Dr Reynolds is founder and principal at JAReynolds & Associates. Prior to his current role, Dr Reynolds
Achillion Pharmaceuticals, a developer of small molecule drugs, has reported a net loss of $8.69m, or $0.33 per share, for the fourth quarter ended December 31, 2008, compared